TSX: IGX
OTCQB: IGXT

Innovative Leader in Pharmaceutical Films

IntelGenx CORP

Investor Presentation

FEBRUARY 2024

WE MAKE APPROVED DRUGS ***BETTER***

Forward-looking Statements

To the extent any statements made in this presentation contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. IntelGenx Technologies Corp. (“IntelGenx” or the “Company”) has based these forward-looking statements on its current expectations and projections about future events. IntelGenx’s actual results could differ materially from those discussed in, or implied by, these forward-looking statements.

Forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Forward-looking statements include, but are not necessarily limited to, risks and uncertainties, including the difficulty of predicting U.S. Food and Drug Administration and Canadian Therapeutic Products Directorate approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials and finished products, the regulatory environment, tax rate assumptions, the outcome of legal proceedings, fluctuations in operating results and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission and the Ontario Securities Commission. In addition, there is uncertainty about the spread of the COVID-19 virus and the impact it will have on IntelGenx’s operations, the demand for its products, global supply chains and economic activity in general. IntelGenx assumes no obligation to update or revise any forward-looking statement.

Company Snapshot

SEC Registered

IntelGenx Corp.
Founded
2003

TSX (IGX)[1]
CDN **$0.18**

OTCQB (IGXT)[1]
US **$0.14**

Market Capitalization[1]
CDN **$32M**

Outstanding Warrants[1,2]
24M

Shares Issued [1,2]
175M

Insider Beneficial
Ownership[2]
31%

1) As of December 31, 2023
2) Includes securities issued to atai on May 14, 2021

IntelGenx's Superior Film Technologies

Creating Next Generation of Pharmaceutical Products

Oral		Rapidly disintegrating, no need for water, easy to carry and to administer, discreet
Sublingual		Fast disintegration, Increased drug absorption across mucosa leading to high bioavailability, faster onset of action, reduced side effects
Buccal		Intimate and prolonged contact with the mucosa, improved drug permeation reducing first-pass metabolism, limited stomach exposure
Transdermal		Minimally invasive and painless approach compared to injection, avoidance of first-pass drug metabolism, reduced dosing frequency

State-of-the-Art Manufacturing

Film Manufacturing Facility

IntelGenx's is the only Health Canada licensed & GMP compliant facility for pharmaceutical film manufacturing:

17,000 sq ft facility in Montreal
fully GMP compliant

FDA & Health Canada Certified

Drug Establishment License

Dealer's License for Controlled Substances

Cannabis Micro-Processing License

State-of-the-art manufacturing and packaging equipment





Robust Product Pipeline



Transformative Strategic Partnership With atai

Positions IntelGenx as a Leader Within the Novel Therapeutic Field of Psychedelics

IntelGenx has entered into exclusive partnership with atai to develop compounds for the prevention or treatment of mental health diseases or disorders, including compounds that have psychedelic, entactogenic and/or oneirophrenic properties. atai holds approx. 21% of IntelGenx's issued and outstanding shares.

ATAI LIFE SCIENCES

- **Formulation work for VLS-01 (Synthetic DMT) completed, prototype available; clinical batch manufactured; 1st clinical trial launched**
- **Initial discussions for second program underway**

Cannabis VersaFilm® Will Set the Standard for Edible Films

Ease of Use, Avoidance of Swallowing and Pleasant Taste are Key Drivers of Appeal



Likely to replace smoking;
Significantly increased blood levels;
Precision dosing

Source: *Among the 76% who found it appealing, Market Research by the Logit Group 08/2018

Winning Partnerships with Tilray & Heritage Cannabis

Australia

- White label distribution via several distributors
  - Medical Market through MedReleaf Australia
  - Medical Market through Aruba Australia

Canada

Heritage Cannabis

- Medical market distribution to clinics via Opticann
- Distribution to re-sellers: SDM, Hybrid, Abba Canopy, Aurora
- Pharmacy referral pilot program via Opticann – pending national roll-out

Tilray

- IntelGenx has received an initial purchase order for three SKUs (CBD20, THC10, THC10:CBD 10)

Opportunistic explorations of distribution channels for medical and recreational markets around the world

Rizaport®

Our first DCP- and FDA-approved pharmaceutical film product

RIZAPORT®
for Migraines

A proprietary oral thin film formulation of rizatriptan benzoate, the active ingredient in Merck & Co.'s Maxalt®

Commercial partnership with Gensco® Pharma in U.S. (under brand name RIZAFILM®)[1]

- FDA approved April 2023
- IntelGenx to receive royalty payments based on net profits of RIZAFILM®; and is eligible to receive pre-specified payments upon the achievement of certain regulatory and commercial milestones
- **Gensco® Pharma making plans to launch in U.S. in Q2-2024**

Commercial partnership with Exeltis Healthcare S.L. in EU

- **Commercially launched in Spain (September 2021)**
- Exeltis Plans to bring this therapy to migraine patients in additional EU countries in the future

1) RIZAFILM® is a Registered Trademark of Gensco® Pharma Corporation

Exordia® & Buprenorphine Buccal Film

Tackling Additional Large Market Opportunities

Exordia®
for Erectile Dysfunction

Commercial partnership with Aquestive Therapeutics

- Collaboration on CRL response and resubmission
- Safety study in preparation
- **Signed exclusive partnership with leading Men's Health company to market Tadalafil Oral Films in the U.S.**

Buprenorphine Buccal Film
for Long-Term Severe Pain

Commercial partnership with Xiromed

- A generic version of Belbuca® (approved by FDA in 2015)
- CRL received by commercialization partner, Xiromed, in April 2023; Xiromed has filed Amendment and FDA has assigned GDUFA goal date of March 8, 2024 (unless the agency determines a facility inspection is required, in which case, the GDUFA goal date is July 9, 2024)

Mild-to-Moderate Alzheimer's Disease (AD)

Montelukast VersaFilm™

Major Repurposing Opportunity with Tangible Benefits



- Montelukast is a leukotriene receptor antagonist
- Proven ability to reduce neuroinflammation and restore brain cell function
- Possibility as the first-ever disease modifying treatment for AD/PD
- Improved bioavailability
- Demonstrated ability to cross blood-brain barrier
- Overcomes compliance issue in elderly Alzheimer’s Disease patients

Improves Cognitive Functions & Structural Integrity

Montelukast VersaFilm™

Preclinical Demonstration

- ❑ Improves Learning and Memory in aged animals
- ❑ Crosses the Blood-Brain Barrier in rats and humans
- ❑ Restores Blood Vessel Structural Integrity
- ❑ Re-establishes Generation of New Neurons
- ❑ Restores Learning and Memory in a Model of Lewy Body dementia
- ❑ Improves function in a number of models of acute and chronic neurodegenerative diseases

nature COMMUNICATIONS

ARTICLE

Received 9 Dec 2014 | Accepted 24 Aug 2015 | Published 27 Oct 2015 DOI: 10.1038/ncomms9466 OPEN

Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug

Julia Marschallinger[1,2], Iris Schäffner[3], Barbara Klein[1,2], Renate Gelfert[1,2], Francisco J. Rivera[1,2], Sebastian Illes[1,2], Lukas Grassner[1,2,4], Maximilian Janssen[1,2], Peter Rotheneichner[1,2,5], Claudia Schmuckermair[6], Roland Coras[7], Marta Boccazzi[8], Mansoor Chishty[9], Florian B. Lagler[10], Marija Renic[11], Hans-Christian Bauer[2,12], Nicolas Singewald[6], Ingmar Blümcke[7], Ulrich Bogdahn[13], Sebastien Couillard-Despres[2,5], D. Chichung Lie[3], Maria P. Abbracchio[8] & Ludwig Aigner[1,2]

Early Clinical Evidence



Before:
MMSE 13: moderate to severe dementia



After 2 Months:
MMSE 22: Mild Dementia

IntelGenx CORP

1) Note: MMSE = Mini-Mental State Examination; is a test to measure cognitive impairment

Phase I Clinical Study Completed

Montelukast VersaFilm™

Positive Results

A single-dose, non-randomized, open-label, two-way, pilot, comparative bioavailability study of Montelukast 10 mg oral film (IntelGenx Corp.) and Singulair® 10 mg film-coated tablet (Merck & Co., Inc., approved for Asthma in 1998) in healthy male and non-pregnant female volunteers under fasting conditions



CSF level measured for Buccal Film (average of 8)

CSF	ng/mL
Average at 3 hours	3.6
Average at 7 hours	4.2

Safety Results: A total of 2 subjects experienced somnolence when taking the buccal film

IntelGenx CORP

Phase IIa (BUENA) Clinical Study

Montelukast VersaFilm™

Underway



A randomized Phase IIa, multi-center, double-blind, placebo-controlled study to assess the safety, feasibility, tolerability, and efficacy of Montelukast in patients with mild-to-moderate AD

- Study protocol approved by Health Canada
- Subjects ≥50 years of age with mild-to-moderate AD and treated daily with donepezil, rivastigmine or galantamine for ≥3 months
- N=50 with 1:1 randomization Montelukast vs. placebo
- Treatment duration for each patient: 26 weeks
- Assessment of the treatment effect: cognitive abilities and exploratory biomarkers
- Independent Data Safety Monitoring Board completed its first interim analysis in October 2019
- Received Health Canada approval to increase dosage to 2x30mg daily vs 10mg daily in January 2020
- **Enrollment completed August 2023**

Montelukast VersaFilm® for Parkinson's Disease

In Research Collaboration with Karolinska University Hospital and Per Svenningsson, MD, PhD

Market

The estimated total economic burden of PD in 2017 in the US was $51.9 billion

Direct medical cost of $25.4 billion

Indirect and non-medical cost of $26.5 billion

Cause

Microglia involvement via release of pro-inflammatory factors

Inflammation and cell-death of dopamine producing neurons

Treatment

Montelukast to decrease inflammation and reducing neuronal cell death of dopamine-producing cells and ultimately PD-related symptoms

1) Source: Lewin Group Inc., Economic Burden and Future Impact of Parkinson's Disease - Final Report, 2019; Wallin, J.; Svenningsson, P. Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson's Disease. Int. J. Mol. Sci. 2021, 22, 5606

VetaFilm®: Improved Drug Delivery for Companion Animals

Safe Administration, Portability & Therapeutic Benefits

With **VetaFilm®**

VS



Low compliance with treatments for chronic diseases

- Administration challenges
- Rejection of medication
- Stress of animal and care giver

VetaFilm® overcomes all those challenges:

- Specific flavors (chicken liver / roast beef)
- High adherence of films to oral mucosa
- Change of dosing regimen (sustained release / fast absorption) possible
- No first pass metabolism when delivered trans mucosal

December 2023 development and license agreements with Covenant Animal Health

Accomplished Leadership Team

>40 Employees

Experience

Dwight Gorham
CEO

- Accomplished history of senior leadership success in the life sciences industry
- 30+ years CMO / generics / pharma experience (Pillar 5 Pharma, Pharmascience, Accucaps Industries, Burroughs Wellcome, Draxis Pharma, Baker Cummings, Glaxo)
- Strong track record of helping nurture and build great product franchises and businesses

Andre Godin, CPA, CA
President & CFO

- 25+ years biotech/pharma industry experience
- Member of the Canadian Chartered Professional Accountants and the Canadian Institute of Chartered Accountants

Nadine Paiement, M. Sc.
VP, Research & Development

- Co-inventor of IntelGenx Trilayer Technology
- 20 years experience in product development and technology transfer

Tommy Kenny, J.D. LL.B, M.Sc.
SVP, General Counsel of IntelGenx Corp.

- Attorney specializing in intellectual property and commercial pharmaceutical law
- Technical expertise across a range of legal functions - manages litigation and advises on commercial partnerships, while also building a strong IP portfolio IntelGenx's oral film technologies

IntelGenx Advantage

In Summary

- Agreements with global leaders (e.g. atai, Gensco® Pharma, ENDO, Aquestive, Tilray, Heritage Cannabis, Exceltis)
- Emerging leader in psychedelics and cannabis oral films, as well as veterinary films
- Unique drug repurposing opportunity (Montelukast) for the treatment of AD and PD
- Robust product and product candidate pipeline
- Health Canada:
  - Drug Establishment License
  - Dealer's License for controlled substances
  - Cannabis Micro-Processing License







Thank you!

TSX: IGX
OTCQB: IGXT

Innovative Leader in Pharmaceutical Films

IntelGenx CORP

IntelGenx Corporate Offices

6420 Abrams
Saint-Laurent (Quebec)
H4S 1Y2 Canada

www.intelgenx.com

Contacts

Stephen Kilmer
Investor Relations
☎ +1-647-872-4849
stephen@kilmerlucas.com

André Godin, CPA, CA
President & CFO
☎ +1-514-331-7440 ext. 203
andre@intelgenx.com